Wedbush Reiterates Outperform on Rani Therapeutics Hldgs, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Rani Therapeutics Hldgs (NASDAQ:RANI) and maintained a price target of $8. This reaffirms Wedbush's positive outlook on the company's stock.
February 06, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Rani Therapeutics Hldgs and maintained a price target of $8, indicating a positive outlook on the stock.
The reiteration of an Outperform rating and the maintenance of a $8 price target by a reputable analyst like Andreas Argyrides from Wedbush signals a strong vote of confidence in Rani Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in RANI's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100